Ischemix, LLC
Ischemix, Inc. is a privately-held pharmaceutical company dedicated to developing novel, proprietary cytoprotective compounds for the treatment of serious diseases and conditions, including traumatic brain injury (TBI). The company's mission is to advance cytoprotective therapies that can prevent and treat serious health issues, leveraging innovative compounds like CMX-2043. With a focus on safety, efficacy, and patent protection, Ischemix aims to bring effective treatments to market that address unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Patents
Compositions and methods for treating ischemia and ischemia-reperfusion injury
US-9540417-B2
View DetailsCompositions and methods for treating ischemia and ischemia-reperfusion injury
US-8772249-B2
View Details
Compositions and methods for treating ischemia and ischemia-reperfusion injury
US-9540417-B2
View DetailsCompositions and methods for treating ischemia and ischemia-reperfusion injury
US-8772249-B2
View DetailsProducts
Lead small-molecule cytoprotective injectable (clinical candidate)
A small-molecule, injectable cytoprotective candidate derived from alpha-lipoic-acid analogs, engineered for multi-modal activity across tissue types and developed for traumatic brain injury and other ischemic injuries.
Lead small-molecule cytoprotective injectable (clinical candidate)
A small-molecule, injectable cytoprotective candidate derived from alpha-lipoic-acid analogs, engineered for multi-modal activity across tissue types and developed for traumatic brain injury and other ischemic injuries.
Services
End-to-end development services covering medicinal chemistry, preclinical efficacy and safety studies, regulatory-enabling studies and Phase 1 clinical execution in partnership with CROs.
End-to-end development services covering medicinal chemistry, preclinical efficacy and safety studies, regulatory-enabling studies and Phase 1 clinical execution in partnership with CROs.
Expertise Areas
- Cytoprotective small-molecule drug development
- Preclinical efficacy and translational neuroscience (TBI models)
- Clinical trial design and execution (SAD/MAD and randomized Phase 2)
- Preclinical pharmacology and toxicology
Key Technologies
- Alpha-lipoic-acid analog medicinal chemistry
- Rodent and porcine traumatic brain injury models
- Actigraphy-based behavioral monitoring
- Magnetic resonance imaging (MRI) analysis
News & Updates
Ischemix Enrolls First Patient in Phase 2a Trial to Prevent Contrast-Induced Acute Kidney Injury
In June 2014, Ischemix enrolled the first patient in a Phase 2a trial of its lead compound to prevent contrast-induced acute kidney injury in acute coronary syndrome patients undergoing coronary angiography.
Ischemix Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI)
In August 2023, Ischemix announced the successful completion of a Phase 1 trial demonstrating safety and tolerability of CMX-2043 in healthy subjects, preparing for Phase 2 trials.
Ischemix Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)
In July 2021, Ischemix received funding from the US Department of Defense to support Phase 1 studies of CMX-2043 for TBI.
Ischemix Announces Results of Its Phase 2 CARIN Trial
In April 2016, Ischemix announced the results of its Phase 2 CARIN trial, which studied CMX-2043 for prevention of contrast-induced kidney injury and cardiac injury, showing safety but not meeting all endpoints.
Bioorganic and Medicinal Chemistry: Lipoic acid analogs with enhanced pharmacological activity
CMX-2043 Efficacy in a Rat Model of Cardiac Ischemia-Reperfusion Injury
Ischemix Enrolls First Patient in Phase 2a Trial to Prevent Contrast-Induced Acute Kidney Injury
In June 2014, Ischemix enrolled the first patient in a Phase 2a trial of its lead compound to prevent contrast-induced acute kidney injury in acute coronary syndrome patients undergoing coronary angiography.
Ischemix Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI)
In August 2023, Ischemix announced the successful completion of a Phase 1 trial demonstrating safety and tolerability of CMX-2043 in healthy subjects, preparing for Phase 2 trials.
Ischemix Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)
In July 2021, Ischemix received funding from the US Department of Defense to support Phase 1 studies of CMX-2043 for TBI.
Ischemix Announces Results of Its Phase 2 CARIN Trial
In April 2016, Ischemix announced the results of its Phase 2 CARIN trial, which studied CMX-2043 for prevention of contrast-induced kidney injury and cardiac injury, showing safety but not meeting all endpoints.